MeritValue

Mosaic ImmunoEngineering Inc.

CPMVdata completeness 63%15 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'totalDebt'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue—————
Net income−$3.68M1−$2.38M2−$1.01M3−$921,9834−$687,8464
Operating cash flow−$679,2365−$690,1296−$497,4677−$241,1598−$111,3978
Capital expenditure—————
Free cash flow (derived)—————
Total debt—————
Cash & equivalents$226,1429$220,64510$156,17811$115,01912$3,62212
Diluted shares6.7M7.2M7.2M7.2M7.2M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$10.33
your share of equity
Profit it earned you last year
−$0.95
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$10.33 of net worth that earned you −$0.95 last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+8% shares · 5y

Share count is up 8% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.5.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001683168-23-001237 (NetIncomeLoss)
  2. 10-K · period ending 2022-12-31 · accession 0001683168-24-002402 (NetIncomeLoss)
  3. 10-K · period ending 2023-12-31 · accession 0001683168-25-002584 (NetIncomeLoss)
  4. 10-K · period ending 2024-12-31 · accession 0001683168-26-002977 (NetIncomeLoss)
  5. 10-K · period ending 2021-12-31 · accession 0001683168-23-001237 (NetCashProvidedByUsedInOperatingActivities)
  6. 10-K · period ending 2022-12-31 · accession 0001683168-24-002402 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K · period ending 2023-12-31 · accession 0001683168-25-002584 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2024-12-31 · accession 0001683168-26-002977 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2021-12-31 · accession 0001683168-23-001237 (CashAndCashEquivalentsAtCarryingValue)
  10. 10-K · period ending 2022-12-31 · accession 0001683168-24-002402 (CashAndCashEquivalentsAtCarryingValue)
  11. 10-K · period ending 2023-12-31 · accession 0001683168-25-002584 (CashAndCashEquivalentsAtCarryingValue)
  12. 10-K · period ending 2024-12-31 · accession 0001683168-26-002977 (CashAndCashEquivalentsAtCarryingValue)